Topic

Articles

Innovate UK has awarded Epsilogen with further grant funding for the development of the next generation antibody treatments for ovarian cancer.

Innovate UK Awards Epsilogen Further Funding for Ovarian Cancer Treatments

VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.


VAR2 Pharmaceuticals Wins MilliporeSigma’s Advance Biotech Grant

Phesgo is a fixed-dose-combination subcutaneous injection of Perjeta (pertuzumab) and Herceptin (trastuzumab) for treating HER2-positive breast cancer.

FDA approves Roche’s Phesgo, a Fixed-Dose Combination Breast Cancer Drug

The companies have entered into a development and manufacturing agreement for Anthos Therapeutics’ abelacimab for treating thrombotic disorders.

Lonza, Anthos Therapeutics Partner on Anti-coagulant Biologic Abelacimab

The partnership, led by Takeda and CSL Behring, will focus on developing a hyperimmune immunoglobulin against COVID-19.

Global Plasma Providers Partner to Develop Potential COVID-19 Hyperimmune Therapy

The therapy works by transferring pathogen-specific antibodies from plasma gathered from recovered individuals into an infected patient, which may help the patient’s immune system respond and increase recovery.

Takeda to Develop Plasma-Derived Therapy for COVID-19 Treatment

The agreement centers around the development of new stem-cell derived allogeneic T-cell therapies for the treatment of cancer.

Astellas, Adaptimmune Form Cell Therapy Pact Worth Up to $897.5 million

Roche’s ADC, Kadcyla, has been recommended for approval in the EU for for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment.

CHMP Recommends Roche ADC for EU Approval of New Indication

Limitations in traditional flu vaccine manufacturing methods underline the need for shifting to modern technologies.

Modernizing Flu Vaccine Manufacturing

Under a collaboration potentially worth more than $1.5 billion, the companies aim to develop the antisense therapy to treat patients with certain cardiovascular and metabolic diseases.

Therapeutic Specific Areas